全文获取类型
收费全文 | 42211篇 |
免费 | 3020篇 |
国内免费 | 575篇 |
专业分类
耳鼻咽喉 | 188篇 |
儿科学 | 561篇 |
妇产科学 | 532篇 |
基础医学 | 2543篇 |
口腔科学 | 202篇 |
临床医学 | 3812篇 |
内科学 | 4230篇 |
皮肤病学 | 548篇 |
神经病学 | 1548篇 |
特种医学 | 629篇 |
外科学 | 2123篇 |
综合类 | 6227篇 |
预防医学 | 6742篇 |
眼科学 | 265篇 |
药学 | 12115篇 |
23篇 | |
中国医学 | 939篇 |
肿瘤学 | 2579篇 |
出版年
2023年 | 560篇 |
2022年 | 1297篇 |
2021年 | 1645篇 |
2020年 | 1515篇 |
2019年 | 1335篇 |
2018年 | 1336篇 |
2017年 | 1332篇 |
2016年 | 1429篇 |
2015年 | 1552篇 |
2014年 | 3557篇 |
2013年 | 3729篇 |
2012年 | 3143篇 |
2011年 | 3413篇 |
2010年 | 2563篇 |
2009年 | 2352篇 |
2008年 | 2224篇 |
2007年 | 2055篇 |
2006年 | 1714篇 |
2005年 | 1363篇 |
2004年 | 1102篇 |
2003年 | 924篇 |
2002年 | 660篇 |
2001年 | 575篇 |
2000年 | 509篇 |
1999年 | 495篇 |
1998年 | 327篇 |
1997年 | 310篇 |
1996年 | 238篇 |
1995年 | 237篇 |
1994年 | 234篇 |
1993年 | 177篇 |
1992年 | 165篇 |
1991年 | 121篇 |
1990年 | 120篇 |
1989年 | 106篇 |
1988年 | 115篇 |
1987年 | 102篇 |
1986年 | 105篇 |
1985年 | 123篇 |
1984年 | 140篇 |
1983年 | 77篇 |
1982年 | 84篇 |
1981年 | 59篇 |
1980年 | 78篇 |
1979年 | 57篇 |
1978年 | 66篇 |
1977年 | 57篇 |
1976年 | 65篇 |
1975年 | 69篇 |
1974年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 932 毫秒
1.
2.
3.
4.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
5.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
6.
《Journal of pediatric surgery》2023,58(9):1694-1698
BackgroundThe Coronavirus Disease 2019 pandemic provided a natural experiment to study the effect of social distancing on the risk of developing Hirschsprung's Associated Enterocolitis (HAEC).MethodsUsing the Pediatric Health Information System (PHIS), a retrospective cohort study of children (<18 years) with Hirschsprung's Disease (HSCR) across 47 United States children's hospitals was performed. The primary outcome was HAEC admissions per 10,000 patient-days. The exposure (COVID-19) was defined as April 2020–December 2021. The unexposed (historical control) period was April 2018–December 2019. Secondary outcomes included sepsis, bowel perforation, intensive care unit (ICU) admission, mortality, and length of stay.ResultsOverall, we included 5707 patients with HSCR during the study period. There were 984 and 834 HAEC admissions during the pre-pandemic and pandemic periods, respectively (2.6 vs. 1.9 HAEC admissions per 10,000 patient-days, incident rate ratio [95% confidence interval]: 0.74 [0.67, 0.81], p < 0.001). Compared to pre-pandemic, those with HAEC during the pandemic were younger (median [IQR]: 566 [162, 1430] days pandemic vs. 746 [259, 1609] days pre-pandemic, p < 0.001) and more likely to live in the lowest quartile of median household income zip codes (24% pandemic vs. 19% pre-pandemic, p = 0.02). There were no significant differences in rates of sepsis (6.1% pandemic vs. 6.1% pre-pandemic, p > 0.9), bowel perforation (1.3% pandemic vs. 1.2% pre-pandemic, p = 0.8), ICU admissions (9.6% pandemic vs. 12% pre-pandemic, p = 0.2), mortality (0.5% pandemic vs. 0.6% pre-pandemic, p = 0.8), or length of stay (median [interquartile range]: 4 [(Pastor et al., 2009; Gosain and Brinkman, 2015) 2,112,11 days pandemic vs. 5 [(Pastor et al., 2009; Tang et al., 2020) 2,102,10 days pre-pandemic, p = 0.4).ConclusionsThe COVID-19 pandemic was associated with significantly decreased incidence of HAEC admissions across US children's hospitals. Possible etiologies such as social distancing should be explored.Level of evidenceII. 相似文献
7.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献
8.
9.
10.
BackgroundMost patients who have an ankle replacement in the United Kingdom stay in hospital for 2–4 days. This study looked at the safety & cost-effectiveness of a day case ankle replacement pathway.MethodsThis was a retrospective case-control study looking at day case pathway for ankle replacements set up in collaboration with anaesthetists, nurses and physiotherapists. Patients practiced mobilization with crutches before surgery. Patients were discharged home with enough analgesia, and reviewed within 2–5 days of discharge.ResultsTwenty ankle replacements done between November 2017 and November 2019 were reviewed with a mean follow up of 38.4 months. None of these patients required to be readmitted within the first 28 days. No complications were related to the surgery being done as day case. Except one, all patients described the experience as excellent or good.ConclusionPer case the cost savings are estimated to be £880 in comparison to 20 matched inpatient ankle replacements. We conclude that ankle replacements can be safely carried out as day case with appropriate patient selection, pre-operative education and a multi-disciplinary approach. 相似文献